DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Popat, Rakesh; K. Nooka, Ajay; Stockerl‐Goldstein, Keith; Abonour, Rafat; Ramaekers, Ryan; Khot, Amit; Forbes, Adam; Lee, Cindy; Augustson, Bradley; Spencer, Andrew; Mateos, María‐Victoria; Chopra, Bikramjit; Rogers, Rachel; A. Smith, Deborah; Davidge, Jacqueline; Montes de, Rocío; Ferron‐Brady, Geraldine; Yeakey, Anne; K. Talekar, Mala; E. Kremer, Brandon; Gupta, Ira; Quach, Hang

doi:10.1182/blood-2020-139332

Public

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Shared by NobleBlocks on Nov 4, 2020 • 12:00 AM UTC

Authors:

Rakesh Popat

Ajay K. Nooka

Keith Stockerl‐Goldstein

Abstract

Introduction: Single-agent belamaf (GSK2857916), a B-cell maturation antigen-targeting antibody-drug conjugate, demonstrated deep and durable responses with a manageable safety profile in patients with heavily pretreated RRMM (median 7 lines of prior therapy) refractory to an immunomodulatory agent ...

Subject

Bortezomib

Tolerability

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!